Literature DB >> 19837286

Francisella tularensis vaccines.

Petra C F Oyston1.   

Abstract

Francisella tularensis has attracted attention historically as a biological weapon, due to its high infectivity in aerosols, and the severity of disease in humans. There is no licensed vaccine currently available, although an attenuated live vaccine strain (LVS) was identified in the middle of the last century and has been successfully used to protect humans. Efforts are underway to determine the basis of attenuation of LVS, and to understand the immunity required for protection. Alternative approaches to produce subunit vaccines and defined attenuated strains are also in progress. However, the limitations of animal models may make licensing a candidate vaccine challenging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837286     DOI: 10.1016/j.vaccine.2009.07.090

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Identification of early interactions between Francisella and the host.

Authors:  Lydia M Roberts; Shraddha Tuladhar; Shaun P Steele; Kristina J Riebe; Ching-Ju Chen; R Ian Cumming; Sarah Seay; Richard Frothingham; Gregory D Sempowski; Thomas H Kawula; Jeffrey A Frelinger
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide.

Authors:  Michael J Rynkiewicz; Zhaohua Lu; Julia H Hui; Jacqueline Sharon; Barbara A Seaton
Journal:  Biochemistry       Date:  2012-07-02       Impact factor: 3.162

3.  Antibodies to both terminal and internal B-cell epitopes of Francisella tularensis O-polysaccharide produced by patients with tularemia.

Authors:  Zhaohua Lu; Hillary M Perkins; Jacqueline Sharon
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

4.  Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses.

Authors:  Beata Clapp; Jerod A Skyberg; Xinghong Yang; Theresa Thornburg; Nancy Walters; David W Pascual
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

5.  Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection.

Authors:  Sherry L Kurtz; Oded Foreman; Catharine M Bosio; Miriam R Anver; Karen L Elkins
Journal:  Infect Immun       Date:  2012-12-10       Impact factor: 3.441

6.  Targeting the "Rising DAMP" during a Francisella tularensis Infection.

Authors:  Riccardo V D'Elia; Thomas R Laws; Alun Carter; Roman Lukaszewski; Graeme C Clark
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

Review 7.  The Francisella tularensis Polysaccharides: What Is the Real Capsule?

Authors:  Kelly C Freudenberger Catanzaro; Thomas J Inzana
Journal:  Microbiol Mol Biol Rev       Date:  2020-02-12       Impact factor: 11.056

8.  Protective B-cell epitopes of Francisella tularensis O-polysaccharide in a mouse model of respiratory tularaemia.

Authors:  Zhaohua Lu; Guillermo Madico; Marly I Roche; Qi Wang; Julia H Hui; Hillary M Perkins; Joseph Zaia; Catherine E Costello; Jacqueline Sharon
Journal:  Immunology       Date:  2012-07       Impact factor: 7.397

9.  Functional and structural characterization of Francisella tularensis O-antigen antibodies at the low end of antigen reactivity.

Authors:  Zhaohua Lu; Michael J Rynkiewicz; Chiou-Ying Yang; Guillermo Madico; Hillary M Perkins; Marly I Roche; Barbara A Seaton; Jacqueline Sharon
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-08

10.  The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide.

Authors:  Zhaohua Lu; Michael J Rynkiewicz; Chiou-Ying Yang; Guillermo Madico; Hillary M Perkins; Qi Wang; Catherine E Costello; Joseph Zaia; Barbara A Seaton; Jacqueline Sharon
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.